Latest Developments in the Treatment of HCC: A Grand Round Series for VHA Clinicians

A series of 12 CME/CE-certified live meetings led by an expert, accompanied by a downloadable PowerPoint slideset.

Agenda

  • Program Overview
  • Overview of Hepatocellular Carcinoma
  • Very Early–Stage and Early-Stage HCC: Current Best Practices
  • Advanced, Incurable HCC: Latest Developments in Treatment
  • Closing Remarks, Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Chair
David Kaplan, MD, MSc

Associate Professor
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Program Chair
Tamar Taddei, MD

Associate Professor of Medicine
Division of Digestive Diseases
Department of Medicine
Yale University
Director, Liver Cancer Programs
Smilow Cancer Hospital
Yale-New Haven Hospital
New Haven, Connecticut

Faculty
Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Tanios Bekaii-Saab, MD, FACP

Professor
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Faculty
Roniel Cabrera, MD

Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
Director, Hepatology
Medical Director, Liver Transplantation
Division of Hepatology and Nutrition
Department of Gastroenterology
University of Florida
Gainesville, Florida

Faculty
Michael Chang, MD

Faculty
Andres Duarte-Rojo, MD

Faculty
Bassam Estfan, MD

Assistant Professor of Medicine
Department of Hematology and Oncology
Cleveland Clinic Lerner College of Medicine
Professional Staff
Department of Hematology and Oncology
Cleveland Clinic Foundation
Cleveland, Ohio

Faculty
Warren Schmidt, MD

Professor
Division of Gastroenterology/Hepatology
Department of Internal Medicine
University of Iowa
Iowa City, Iowa

Faculty
Keith Stuart, MD

Professor of Medicine 
Division of Hematology/Oncology
Department of Medicine
Tufts University of Medicine
Boston, Massachusetts
Chairman
Department of Hematology/Oncology
Lahey Hospital and Medical Center
Burlington, Massachusetts

CME

Goal Statement
The goal of this activity is to improve participants’ competence in selecting and applying optimal therapeutic strategies for veterans with hepatocellular carcinoma.

Target Audience
This program is intended for oncologists, hepatologists, registered nurses, and other healthcare professionals who care for veterans with hepatocellular carcinoma.

Learning Objectives

  • Select the optimal, evidence-based treatment modality for patients with potentially curable HCC
  • Plan therapeutic strategies for patients with incurable, advanced-stage HCC
  • Gain understanding of agents and therapeutic strategies that have shown a survival benefit for patients with HCC and disease progression after sorafenib
  • Evaluate the available data on promising investigational treatment options for advanced HCC

Accreditation

Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education

ACPE logo

Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-725-L01-P

Type of Activity
Application

Upon receipt of the completed activity evaluation form, you will receive an email from Postgraduate Institute for Medicine within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.